Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added publication reference: Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Semin Cancer Biol. 2025;109:101-124 (Epub Jan 23, 2025).
    Difference
    0.1%
    Check dated 2026-04-03T05:28:53.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a Publications entry for the 2026 Oncologist article with PubMed auto-fill notes and removed the Revision: v3.4.3 entry.
    Difference
    0.3%
    Check dated 2026-03-19T22:14:21.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.3, replacing Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T20:23:00.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    Site update from v3.4.1 to v3.4.2 involves minor UI/bug fixes and no substantive changes to the study record or its critical information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T01:49:34.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Revision: v3.4.1 is now displayed, replacing the previous v3.4.0. This is a minor site metadata update and does not alter the study details.
    Difference
    0.1%
    Check dated 2026-02-04T23:43:09.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Show glossary added and ORR/DCR definitions updated to RECIST 1.1 criteria with duration notes (e.g., 'Throughout study duration, up to approx 80 months'). Additionally, metadata updates were added, including 'Last Update Submitted that Met QC Criteria', 'Revision: v3.4.0', and 'No FEAR Act Data'.
    Difference
    0.8%
    Check dated 2026-01-28T19:50:42.000Z thumbnail image

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.